Foamix Extends Collaboration with Galderma
in the development of dermatological foam medications today announced that
the company has extended its agreement with Galderma to develop an innovative
medicated foam for an additional dermatological indication. This new
treatment contains a novel drug for the therapy of certain skin diseases.
Under this agreement, Foamix will develop the foam formulation of the
product and Galderma will subsequently conduct all other activities
(clinical, non-clinical, etc). Foamix will receive staged payments on
successful completion of the technical milestones of the project.
Headquartered in Rehovot,
topical and mucosal foams for dermatological and gynecological applications.
Foamix’s state-of-the-art foams provide controlled delivery of a variety of
active ingredients. Foamix is currently collaborating with major, medium and
small pharmaceutical and cosmetic companies on a plurality of projects in the
development of proprietary dermatological and gynecologic foam drugs.
Additionally, the Company has an in-house pipeline of dermatological and
gynecological drugs in foam presentation.
To date, Foamix has seventeen issued patents worldwide covering its foam
and OilGel technology platforms and in excess of 150 pending applications of
which more than a third are filed in
leading U.S. patent counsel (WilmerHale LLC).
For additional information, please visit http://www.foamix.co.il.
SOURCE Foamix Ltd